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Abstract
Optimal treatment for patients with only local prostate cancer recurrence after external beam radiation therapy 
(EBRT) failure remains unclear. Possible curative treatments are radical prostatectomy, cryosurgery, and brachyther-
apy. Several single institution series proved that high-dose-rate brachytherapy (HDRBT) and pulsed-dose-rate 
brachytherapy (PDRBT) are reasonable options for this group of patients with acceptable levels of genitourinary and 
gastrointestinal toxicity. A standard dose prescription and scheme have not been established yet, and the literature 
presents a wide range of fractionation protocols. Furthermore, hyperthermia has shown the potential to enhance the 
efficacy of re-irradiation. 
Consequently, a prospective trial is urgently needed to attain clear structured prospective data regarding the effi-
cacy of salvage brachytherapy with adjuvant hyperthermia for locally recurrent prostate cancer. The purpose of this 
report is to introduce a new prospective phase II trial that would meet this need. The primary aim of this prospective 
phase II study combining Iridium-192 brachytherapy with interstitial hyperthermia (IHT) is to analyze toxicity of the 
combined treatment; a secondary aim is to define the efficacy (bNED, DFS, OS) of salvage brachytherapy. The dose 
prescribed to PTV will be 30 Gy in 3 fractions for HDRBT, and 60 Gy in 2 fractions for PDRBT. During IHT, the pros-
tate will be heated to the range of 40-47˚C for 60 minutes prior to brachytherapy dose delivery. The protocol plans for 
treatment of 77 patients. 
J Contemp Brachytherapy 2015; 7, 3: 254-258 
DOI: 10.5114/jcb.2015.51871
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Purpose
Approximately 10% of low-risk group patients and 
up to 60% of high-risk group patients will experience bio-
chemical recurrence (BF) [1-3]. Generally accepted and 
most commonly applied definition of biochemical failure 
after definitive RT is the Phoenix definition (PSA increase 
of > 2 ng/ml above the nadir reached after RT) [4]. Met-
astatic or both metastatic and local disease are found in 
about 50% of patients with biochemical progression who 
have undergone previous radiotherapy. Local recurrence 
only is found in 25% of patients with biochemical pro-
gression. The majority of local recurrences occur at the 
site of dominant primary tumour [5]. 
There is no consensus with respect to optimal treat-
ment in previously irradiated patients with sole local re-
currence of prostate adenocarcinoma. There are only two 
potentially curative treatment modalities for previously 
irradiated recurrent prostate cancer: salvage surgery or 
salvage brachytherapy; these have very similar efficacy 
but different toxicities [6]. Salvage prostatectomy series 
have demonstrated durable long term control. However, 
aggressive salvage treatment options should be offered 
with great care, because reported failure rates as well as 
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toxicity rates can be significant, especially in inexperi-
enced hands, regardless of salvage technique [7]. Other 
treatment possibilities such as cryotherapy or high-in-
tensity focused ultrasound (HIFU) are useful only for 
carefully selected patients. In addition, HIFU is currently 
not recommended as an alternative to accepted curative 
treatment approaches for localized prostate cancer [8]. 
Androgen deprivation should be considered a pal-
liative treatment. It is also not well tolerated by most 
patients and has many side effects, e.g. insulin resist-
ance and diabetes, bone loss, fatigue, sexual dysfunction 
(erectile impotence, loss of libido), symptomatic gyneco-
mastia, hot flushes, anaemia, and cardiovascular events. 
Before deciding to perform local salvage therapy, me-
tastases to regional lymph nodes and distant metastases 
should be ruled out. It is also crucial to identify patients 
that are most likely to have only local disease. Factors that 
are associated with better biochemical control included 
post-treatment PSA nadir of < 0.5 ng/ml, presalvage 
PSA < 10, Gleason score < 8, PSADT (PSA doubling time) 
> 6 months, disease free interval > 24 months, and low 
risk initial tumor [6]. 
To date, there remains no consensus on standard 
dose and fractionation scheme for salvage prostate HDR 
brachytherapy. Previously published series of cases, as 
well as ABS guidelines contain a wide range of prescribed 
doses and various fractionation schemes [9]. 
Prostate brachytherapy allows the administration of 
a high radiation dose in a small volume of tissue. Both 
temporary implants (Ir-192) and permanent implants 
(I-125, Pd-103) have been used for treatment of prostate 
cancer recurrence after EBRT. There are few available 
publications on HDRBT or PDRBT; most of them are ret-
rospective studies that apply to small groups of patients 
[10-16]. The results and toxicity are summarized in the 
Table 1. 
Preclinical studies have clearly demonstrated that 
hyperthermia has the potential to enhance radiation re-
sponse by a factor of 1.4-2.0 [17]. In patients with radio-
resistant prostate cancer, the addition of hyperthermia 
could potentially break down radiation resistance and 
increase the chance of cure. 
Consequently, a prospective trial is urgently needed 
to attain clear structured prospective data regarding the 
efficacy of salvage brachytherapy with adjuvant hyper-
thermia for locally recurrent prostate cancer. The purpose 
of this report is to introduce a new prospective phase 2 
trial that will evaluate the safety and effectiveness of tem-
porary brachytherapy in combination with interstitial hy-
perthermia as a treatment for local recurrence of prostate 
cancer after EBRT. The study will examine the side effects 
of combined treatment, as well as its ability to cure the 
cancer. A protocol of this clinical trial was designed by 
the radiation oncologists from Krakow (Poland) and Er-
langen (Germany) as an international multicenter study. 
Material and methods 
Study design 
This is a prospective, multicenter non-randomized 
phase II study. Patients are recruited during the radiation 
therapy consultation in participating centers. 
Eligibility criteria 
Men with biopsy-confirmed locally recurrent prostate 
adenocarcinoma in stage T1b-T3b N0/pN0 M0 are eligi-
ble for the study. Biopsy should be performed less than 
6 months before registration and more than 24 months af-
ter initial EBRT. As evaluated with a TRUS volume study 
performed 0-4 weeks before registration, each patient 
should meet the eligibility criteria for prostate brachyther-
apy as follows: prostate/tumor volume < 60 ml, 
the distance between rear prostate edge and rectal mu-
cosa > 5 mm, interference of pubic arch ruled out, and, if 
local stage T3b, it must be possible to cover the entire can-
Table 1. Toxicity and outcomes of salvage brachytherapy for prostate cancer recurrence after external beam 
irradiation
Study, year Salvage therapy n Median follow-up 
(months)
Grade 3/4 toxicity Outcome
Łyczek et al. [10] HDR
30 Gy/3 fx/3 impl
115 No information 12.2% GU
0.9% GI
46% bPFS in patients with PSA < 6 
18% bPFS in patients with PSA > 6
Scala et al. [11] HDR
36 Gy/6 fx/2 impl
10 18.5 70% grade 2  
or greater
70% dfs
Jo et al. [12] HDR
22 Gy/2 fx/1 impl
11 29 0% 63% bNED
Morikawa et al. [13] HDR
32 Gy/4 fx/1 impl
29 22 0% 79% bDFS
Chen et al. [14] HDR
36 Gy/6 fx/2 impl
52 59.6 2% 51% 5y bDFS
Lahmer et al. [15] PDR
60 Gy/2 impl
18 21 0-17% 57% PSA-rfsp
Kukiełka et al. [16] HDR + IHT
30 Gy/3 fx/3 impl
25 13 0% 74% 2y bDFS
PSA-rfsp – PSA-recurrence free survival probability, bDFS – biochemical disease-free survival, bPFS – biochemical progression-free survival, bNED – biochemical no 
evidence of disease, HDR – high-dose-rate brachytherapy, PDR – pulsed-dose-rate brachytherapy, IHT – interstitial hyperthermia; impl – implantation 
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cer infiltration by the prescribed minimum brachythera-
py dose. 
The exclusion criteria are: TURP/prostatic salvage 
cryosurgery/HIFU performed more than 6 months be-
fore registration, previous prostatectomy, androgen 
deprivation therapy within 3 months prior to registra-
tion, performance status ECOG > 2, International Pros-
tate Symptoms Score (IPSS) > 20, PSA doubling time 
< 6 months, baseline gastrointestinal (GI) or genitouri-
nary (GU) toxicity grade ≥ 2 as defined in Common Ter-
minology Criteria for Adverse Events (CTCAE) version 
4.0 [18]. Written study-specific informed consent will be 
obtained from all the patients before study registration. 
Primary endpoint 
To estimate the rate of late Grade ≥ 3 gastrointestinal 
(GI) and genitourinary (GU) toxicities related to salvage 
treatment for locally recurrent prostate cancer after pre-
vious external beam radiation therapy. Treatment-related 
toxicity will be evaluated according to the Common Tox-
icity Criteria for Adverse Events version 4.03 (CTCAE). 
Secondary endpoints 
1. To estimate the rate of acute treatment-related GI/
GU adverse events. 2. To determine time to biochemical 
failure (Phoenix definition [4])/ biochemical disease-free 
survival (bDFS), overall survival (OS), disease-free sur-
vival (DFS), disease-specific survival (DSS), and clinical 
patterns of tumor recurrence (time to local tumor pro-
gression or distant failure), as well as pre-treatment prog-
nostic and/or predictive factors. 
Sample size considerations 
The sample size is calculated with type I error of 0.025, 
type II error of 0.2 (power of 80%), and a one-sided hy-
pothesis (only excess of cases is of interest). Conservative-
ly assuming a ‘normal’ rate of 10% grade 3 or higher late 
toxicity, 70 patients are needed to exclude that the rate is 
actually ≥ 20%, i.e., unacceptable, with the necessary pre-
cision. This sample size calculation is based directly on 
the binomial distribution. Adjusting the number of cases 
for ineligible or unanalyzable cases by 10%, a minimum 
sample size of 77 patients is required for this study. 
Brachytherapy 
Implantation procedure 
The implant procedure will be performed according to 
the standard technique. A Foley catheter will be inserted 
to visualize the urethra at the beginning of the procedure. 
The patient will be positioned in the lithotomy position, 
centered on the table. The ultrasound probe will be in-
serted into the rectum and adjusted to provide a satisfac-
tory image without distorting the contour of the prostate. 
Row #1 on the template matrix is positioned within the 
prostate on the axial image, on which the prostate is most 
posteriorly situated and is anterior to the rectum at all 
levels. Afterloading catheters may be placed with TRUS 
or MR guidance. The implant catheters must be non-me-
tallic (for hyperthermia use). The implant procedure may 
be done under spinal or general anesthesia. During the 
implant, attention should be given to keep the catheters 
in the prostate without perforating the urethra. Posterior 
rows of catheters may be advanced into the seminal vesi-
cles under TRUS guidance. 
Treatment planning transrectal ultrasonography 
Treatment planning will be based on a real time TRUS 
volume study of the prostate. It is acceptable also to use 
MRI based treatment planning. The ultrasound probe 
will be advanced until the base of the prostate is visu-
alized, and this level will be designated the base plane. 
Contiguous serial axial images of the prostate at ≤ 3 mm 
increments beginning 5-10 mm cranial to the base plane 
(including all the catheters tips) will be obtained and 
will extend > 5 mm inferior (caudal) to the apex of the 
prostate. The CTV will be outlined on each axial image 
where it is present. The use of dwell time in dwell posi-
tions located outside of the PTV is discouraged to min-
imize normal tissue irradiation. A dwell time optimiza-
tion program based on geometric or inverse and manual 
planning algorithm may be used. 
The target volume definitions are largely based on 
those provided in ICRU Report 58: Dose and Volume 
Specification for reporting interstitial therapy [19]. The 
Clinical Target Volume (CTV) for stages T1-T2 includes 
the TRUS-defined prostate volume. For T3 stages, the 
CTV includes the whole prostate gland and extracapsu-
lar/seminal vesicle invasion. The Planning Target Vol-
ume (PTV) is the same as CTV. Additional 1-3 mm mar-
gins may be added in case of uncertainty of extracapsular 
infiltration. 
Dose specifications, dose fractionation 
In this trial, the dose prescribed to the PTV will be 30 Gy 
in three 10 Gy fractions spaced 21 days apart for HDRBT 
(the most common fractionation scheme in Poland) and 
60 Gy in 2 fractions spaced 28 days apart for PDRBT 
(scheme from Erlangen). In both protocols, the brachyther-
apy will follow interstitial hyperthermia treatment. 
To compare the expected biological effect of different 
fractionation schedules, the calculations were made using 
the linear-quadratic model [20] for the total biologically 
equivalent doses in 2-Gy fractions EQD2 both for HDRBT 
and PDRBT with multiple fractions (see Table 2). 
Dose-volume histogram (DVH) parameters, 
reporting 
The following dose parameters for CTV must be re-
ported: D90, DMIN, V100, V150, V200. The essential condi-
tions are: D90 > 100%, V100 > 90-95%. The required DVH 
parameters for the rectum and bladder (if contoured) are 
D0,1cc, D1cc, D2cc. The dose constraint for the rectum is D2cc 
< 50 Gy (EQD2 for α/β = 3) (for HDRBT D2cc < 7.75 Gy 
per fraction), and for the bladder is D2cc < 60 Gy (EQD2 
for α/β = 3) (for HDRBT D2cc < 8.6 Gy per fraction). The 
urethra DVH parameters are D0,1cc, D10, and D30. The dose 
constraint is D0,1cc < 120% of the prescribed dose. 
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Hyperthermia 
Interstitial hyperthermia (IHT) treatment is scheduled 
before every brachytherapy fraction and it should end no 
more than one hour before the start of irradiation. Hy-
perthermia will be carried out in accordance with the QA 
guidelines published by the RTOG for interstitial hyper-
thermia [21]. Catheters implanted to the prostate during 
the implantation procedure will be used to place micro-
wave antennas and temperature probes. At least eight, 
but as many catheters as possible should be placed in the 
prostate for microwave antennas and thermal sensors. 
The distance between antennas should be at least 5 mm 
and at most 15 mm.
Thermometry probes should be positioned in the 
rectum and urethra near the prostate implant catheters, 
inside the urinary catheter, and in the prostate tissue (at 
least 2 probes) for continuous thermometry and thermal 
mapping of tumor-related temperatures. The objective of 
treatment is to achieve a tumor/prostate temperature of 
40-47°C. Therapeutic time starts when 40°C is achieved 
in at least one of the prostatic thermometry sensors or 
30 minutes after enabling power. Planned treatment time 
is 60 minutes, and a maximum duration of 90 minutes of 
applied power is permitted. Failure to achieve 40°C in at 
least one prostate location for 30 minutes in at least two 
sessions will make the case not evaluable for response and 
toxicity. Hyperthermia withdrawal or shortening thera-
peutic time to 30 minutes is permitted in case of: 1. early 
weakening of spinal anaesthesia; 2. excessive patient mo-
bility (risk of catheter displacement) or 3. patient request. 
Treatment schedules 
For HDR brachytherapy: 
Day 1: IHT for 60 minutes followed by HDR within 60 min; 
Day 22: IHT for 60 minutes followed by HDR within 60 min;
Day 43: IHT for 60 minutes followed by HDR within 60 min.
For PDR brachytherapy:
Day 1-3: IHT 60 minutes followed by PDR within 60 min;
Day 29-31: IHT 60 minutes followed by PDR within 60 min.
Study duration 
The protocol was activated in February 2014 after re-
ceiving the vote of Ethics Committee of Chamber of Phy-
sicians in Krakow. The duration of patient recruiting is 
scheduled for approximately 3-4 years. 
Conclusions
The standard dose prescription and schedule are not 
established yet for salvage brachytherapy re-irradiation of 
locally recurrent prostate cancer. The literature presents 
a wide range of treatment protocols. Consequently, a pro-
spective trial is urgently needed to attain clear structured 
prospective data. The purpose of this report is to introduce 
a new prospective phase 2 trial combining Iridium-192 
brachytherapy with interstitial hyperthermia (IHT). The 
primary aim of this trial is to analyze toxicity of the com-
bined treatment, and the secondary aim is to define the 
efficacy (bNED, DFS, OS) of salvage brachytherapy and 
heat. The radiation dose prescribed to the PTV is 30 Gy in 
3 fractions for HDR-brachytherapy and 60 Gy in 2 fractions 
for PDR-brachytherapy. The thermal dose prescribed to 
the PTV is a range of 40-47°C for 60 min. The protocol an-
ticipates treatment of 77 patients and the trial is currently 
open for participation by additional study centers. 
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